Testosterone Petition From Public Citizen Eyes Industry Bias In Risk Findings
This article was originally published in The Pink Sheet Daily
Executive Summary
Seeking immediate relabeling of the products, advocacy group notes a meta-analysis found different CV risk depending on who funded the studies analyzed.
You may also be interested in...
Disease Awareness Campaigns Still Must Tread Carefully, Observer Says
Sponsored plotline for General Hospital was careful to avoid irking US FDA; agency withdrew its guidance on disease awareness campaigns in 2015, but its influence appears to be continuing, according to a former official.
REMS Can’t Help Endo’s Aveed – Won’t Address Unpredictable Safety Events, FDA Advisors Say
Without predictive factors to determine who is likely to get a severe post-injection reaction, FDA advisory committees say Endo’s proposed REMS for its long-acting testosterone is unlikely to allay safety concerns.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.